Highlights•mAbs mixture targeting independent epitopes are better therapeutics.•Optimizing
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …

The brutal toll of another viral pandemic can be blunted by investing now in research that
uncovers mechanisms of broad-based immunity so we may have vaccines and therapeutics …

In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from
single B cells of the COVID-19–recovered individuals in India who experienced ancestral …

Developing potent therapeutics and effective vaccines are the ultimate goals in controlling
infectious diseases. Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects …

Paramyxoviruses—including important pathogens like parainfluenza, measles, and Nipah
viruses—use a receptor binding protein [hemagglutinin-neuraminidase (HN) for …

Due to its high mortality rate and continued re-emergence, Ebolavirus disease (EVD)
continues to pose a serious threat to global health. A group of viruses within the genus …

Viruses in the family Filoviridae, including the commonly known Ebola (EBOV) and Marburg
(MARV) viruses, can cause severe hemorrhagic fever in humans and nonhuman primates …

The envelope glycoprotein GP of the ebolaviruses is essential for host cell entry and the
primary target of the host antibody response. GP is heavily glycosylated with up to 17 N …

Despite increasing evidence that uveitis is common and consequential in survivors of Ebola
virus disease (EVD), the host-pathogen determinants of the clinical phenotype are …

The three human pathogenic ebolaviruses: Zaire (EBOV), Bundibugyo (BDBV), and Sudan
(SUDV) virus, cause severe disease with high fatality rates. Epitopes of ebolavirus …